Pfizer chief's pay leaps 17% to $14.8M

It's good to be Jeff Kindler (photo) these days. The Pfizer CEO recently bagged the biggest pharma deal around, with his $68 billion acquisition of Wyeth. The analysts who were agitating for him to make a big move are appeased, for now. And at a time when jobs are scarce and raises even more so, he got a 17 percent hike in 2008 pay.

His entire compensation package? $14.79 million, according to the Associated Press. His base salary grew 8 percent to $1.58 million, though it remained a small fraction of his overall pay. Performance-based cash bonus: $3 million. Stock and option awards: $9.78 million. (About a quarter of that, however, was options with a $22.55 strike price; at press time the stock was trading at $14.79.) The balance is made up in use of the company plane, home security, financial counseling, and use of a car.

Meanwhile, the Wall Street Journal values Kindler's pay at $13.1 million--but that number is calculated differently. BNet Pharma notes that Pfizer put the lower number in its proxy under "total direct compensation." Elsewhere in the proxy lies a summary compensation table, and Pfizer itself reminds us that the total direct numbers aren't intended to replace the other version.

- read the AP story
- check out the post at the WSJ Health Blog
- see the BNet item

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.